Loading...
•
Dec 31, 2024
•/
Valneva Q4 2024 Earnings Report
Valneva reported Q4 2024 results, swinging to a net loss with sequential revenue growth driven by IXIARO and IXCHIQ sales.
Key Takeaways
Valneva posted €53 million in revenue for Q4 2024, but recorded a net loss of €36.9 million, impacted by higher R&D and finance expenses. Despite robust vaccine sales, profitability deteriorated from prior quarters.
Q4 revenue reached approximately €53 million.
Net loss of €36.9 million in the quarter, reversing prior profitability.
Strong contributions from IXIARO and first-time IXCHIQ sales.
Increased R&D and finance costs weighed heavily on results.
Valneva
Valneva
Valneva Revenue by Segment
Valneva Revenue by Geographic Location
Revenue by Segment
IXIARO Revenue
CapyFin.comDUKORAL Revenue
CapyFin.comIXCHIQ Revenue
CapyFin.comThird-party products Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comCanada Revenue
CapyFin.comUnited Kingdom Revenue
CapyFin.comGermany Revenue
CapyFin.comAustria Revenue
CapyFin.comNordics Revenue
CapyFin.comFrance Revenue
CapyFin.comOther Europe Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Valneva expects continued sales growth in travel vaccines and strong momentum in the launch of IXCHIQ while focusing on R&D pipeline advancement.
Positive Outlook
- Solid demand for IXIARO and DUKORAL expected to continue.
- Full-year profitability targeted for 2025.
- Further regulatory submissions for IXCHIQ planned.
- Strategic partnerships expected to enhance pipeline progress.
- Continued support from CEPI and EU for vaccine development.
Challenges Ahead
- High R&D expenses will continue to impact short-term earnings.
- Potential FX headwinds from USD and SEK fluctuations.
- Competition in travel vaccines could pressure pricing.
- Uncertainties regarding Lyme disease vaccine commercialization timing.
- High borrowing costs continue to weigh on financial results.